PCI helps to translate discoveries and ideas created at the University of Pennsylvania into new products and businesses for societal benefit.

We actively facilitate a broad range of technology development connections between Penn and the private sector. Whether the end result is a technology license, an R&D alliance, or the formation of a new venture, PCI serves as a dedicated one-stop shop for commercial partnering with Penn.

Access the FY2025 Year in Review

#1

in licensing revenue 5th year in a row

26

Startups launched

>$591M

in investment capital raised or received by Penn affiliated startups

99

New patents awarded

Read the report here

Open Source Software

Download our latest Faculty Guide to Open-Source Software Licenses here.

Penn Faculty Receive ARPA-H Awards for Gene Therapy Research

The Advanced Research Projects Agency for Health (ARPA-H) awarded $43 million to Philadelphia gene therapy researchers to advance treatments for rare diseases. The recipients include:  

• GEMMA Biotherapeutics, a Penn spinout co-founded by Jim Wilson, MD, PhD, emeritus professor in Penn Medicine, to develop gene therapies using AI. 
• CHOP, to support a team led by Kiran Musunuru, MD, PhD, the Barry J. Gertz Professor for Translational Research at Penn Medicine, and Rebecca Ahrens-Nicklas, MD, PhD, Director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program (GTIMD) at Children’s Hospital of Philadelphia, which is developing a platform for treating rare genetic, liver-related diseases in infants and children. 

This funding will support the advancement and scaling of groundbreaking treatment opportunities for patients. Learn more here.  

Kira Pharmaceuticals to Merge with Jasper Therapeutics

Kira Pharmaceuticals announced its merger with Jasper Therapeutics, alongside $132 million in financing to advance biologic therapies for immune-mediated diseases.  
 
Kira was co-founded by Wenchao Song, PhD, Professor of Systems Pharmacology and Translational Therapeutics at Penn Medicine, and has built a differentiated complement therapy portfolio that will strengthen the combined company’s pipeline of treatments and support development through the second half of 2028.  Read more here.